AKT inhibition effective against TNBC

The findings of a phase II trial indicate that the AKT inhibitor ipatasertib is superior to placebo in patients with metastatic triple-negative breast cancer. Patients receiving ipatasertib had a median progression-free survival of 6.2 months, versus 4.9 months in patients who received placebo (P = 0.037). Grade 3 diarrhoea was the commonest serious adverse event, affecting 23% of patients in the ipatasertib group. These findings indicate the need for further investigations of the efficacy of ipatasertib.